Author Affiliations: Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Center (Drs Wilson, Haik, and Dyer), and Departments of Surgery (Drs Wilson and Haik), Pathology (Dr Wilson), and Developmental Neurobiology (Dr Dyer), Division of Ophthalmology (Drs Wilson and Haik), St Jude Children's Research Hospital, Memphis, Tennessee.
In 2008, Abramson and colleagues1 brought to our attention the unprecedented response of intraocular retinoblastoma to superselective intraophthalmic artery chemotherapy (SSIOAC), which rapidly became a primary treatment for both unilateral and bilateral intraocular retinoblastoma2,3 adopted by retinoblastoma centers worldwide. The enthusiasm for SSIOAC results from the reported dramatic responses and mitigated toxicities associated with primary systemic chemotherapy. Nonetheless, reservations regarding the technique have been voiced,4-7 and although others have pushed ahead, we are hesitant to adopt SSIOAC for our patients.
Wilson MW, Haik BG, Dyer MA. Superselective Intraophthalmic Artery Chemotherapy: What We Do Not Know. Arch Ophthalmol. 2011;129(11):1490–1491. doi:10.1001/archophthalmol.2011.361
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: